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During the current Severe Acute Respiratory Syndrome 2 
(SARS-CoV-2) virus outbreak, we have observed a particu-
lar phenomenon in medical publications. Many observa-
tional studies without control groups are published in major 
journals. The first series of 1099 patients with COVID-19 
is a descriptive study without a control group [1]. Thus, we 
do not know, for example, whether the frequency of diarrhea 
in coronavirus disease 2019 (COVID-19) patients (3.8%) is 
higher or lower than that in patients with influenza. In the 
time of the pandemic, there is a need for rapid information 
to decide how to best treat patients, and how to best curtail 
the spread of the virus; hence, the publication of these types 
of studies may be justifiable.
Already in medical school, we learn that in the evidence 
hierarchy, randomized clinical trials (RCTs) are positioned at 
the top, because they eliminate many possible biases, such as 
selection bias and other possible confounders that are diffi-
cult to adjust. The first RCT in clinical medicine was a study 
in 1948 of 55 patients who received streptomycin, compared 
with 52 control patients, for the treatment of tuberculosis [2]. 
However, RCTs require considerable advance planning and 
approval processes and are costly. One systematic review of 
RCT costs found, among relatively scant published informa-
tion, that the median costs per recruited patient were US$ 
409 and the overall costs per RCT ranged from US$ 0.2 
million to 612 million [3]. Performing RCTs is thus reserved 
for the pharmaceutical industry and academics with strong 
funding. This poses a problem during the COVID-19 pan-
demic and will likely continue to do so after the pandemic. 
The inevitable economic recession may cause a reduction of 
research funding. Therefore, it is good to reconsider the role 
of RCTs as the primary study design of choice.
Equipoise
The decision to perform an RCT needs to consider appro-
priate use of research resources, trying to answer relevant 
questions and following best ethical principles. Doctors and 
researchers simply cannot test all ideas for possible treat-
ments that come to their mind by way of RCTs. A principle 
proposed several decades ago, called equipoise, should be 
considered by doctors, researchers and ethics committees 
[4]. This principle requires that a clinical trial should be 
performed only if there is genuine uncertainty about which 
treatment is beneficial. When a treatment can be predicted 
to be effective by the medical community, or when the bio-
logical plausibility is clear and beyond doubt, or on the other 
hand, totally absent (for example, the use of Reiki for treat-
ing COVID-19), RCTs should normally not be undertaken. 
While these criteria appear self-explanatory, we are aware 
of many trials that lacked equipoise and were published in 
major medical journals. One such example is a trial that 
compared chlorhexidine–alcohol with povidone-iodine alone 
for surgical skin antisepsis, published in the clinical journal 
with the highest impact factor in the world [5]. If one asks 
infection prevention practitioners, they would be perfectly 
able to predict the results of this RCT at the outset. Alcohols 
were known for decades to be more potent than aqueous 
povidone-iodine, and the comparison was unfair by way of 
comparing two antiseptics against one.
In finding a treatment for COVID-19, the principle of 
equipoise should remain applicable for a clinical trial, even 
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though the situation is often not clear-cut. One example is 
the proposal to treat COVID-19 patients with plasma of 
recovered patients. Based on immunological reasoning and 
on experience with some other viral diseases, this treatment 
is clearly plausible. However, the comparator, the standard of 
care, at the moment is the best treatment available, and there 
are risks of adverse events, such as transfusion-related acute 
lung injury and antibody-dependent viral enhancement.
RCTs are generally slow in providing answers. A search 
performed on April 28, 2020, in the ClinicalTrials.gov data-
base showed that among 311,349 registered trials on adults 
up to December 31, 2018, only 39,601 (13%) had published 
their results, only half of the RCTs achieved the recruitment 
target, and only half of these were completed in time.
Clinical trials ethics during outbreaks
During the Ebola virus outbreak in 2014, an ethics advisory 
panel to the World Health Organization (WHO) concluded 
that it would be acceptable to offer unregistered interven-
tions that have shown promising results in the laboratory and 
in animal models, but have not yet been evaluated for safety 
and efficacy in humans, provided that certain conditions are 
met (https ://www.who.int/csr/resou rces/publi catio ns/ebola /
ethic al-consi derat ions/en/). The essence from this viewpoint 
has been applied in several studies concerning treatment of 
COVID-19 with hydroxychloroquine. Some early observa-
tions indicated that this agent may be effective, but some 
were later rebuked by the scientific community [6]. To us, 
the unfortunate aspect of this example does not appear to 
be the contradiction of results by different studies—which 
is an inherent aspect of how science works—but the fact 
that those observational studies were not conducted suffi-
ciently well, i.e. included analyses without adjustment, had 
no proper control group, and used cases and controls from 
different patient populations [6].
Alternative to RCTs
Observational studies—either cohort or case–control—can 
indeed answer clinical questions when they are performed 
well. Guidelines for reporting observational studies are 
available, such as the STROBE statement (https ://www.strob 
e-state ment.org/index .php?id=strob e-home). The STROBE 
statement was developed by an international, collaborative 
initiative of epidemiologists, methodologists, statisticians, 
researchers, and journal editors involved in the conduct 
and dissemination of observational studies. Observational 
studies can answer more, and more diverse, questions than 
RCTs. This includes, for example, outcomes observed dur-
ing various follow-up durations and also side effects. RCTs 
are less suitable for answering these questions, because the 
follow-up duration is often fixed, and it is more difficult 
to recruit larger study populations. In addition, RCTs are 
usually powered to observe outcomes, but not side effects. 
Unfortunately, the possibility to ‘adjust’ the study size, the 
duration of follow-up and other variables, such as what out-
comes to include or not to include, is an important threat 
to this type of study design. It becomes the task of editors, 
peer-reviewers and the research community to detect such 
problems. Systematic reviews that analyze and summarize 
observational studies are able to rate the quality of such 
studies and detect if there is publication bias, such as when 
only studies with ‘positive’ results tend to get published. 
The advent of some journals—unfortunately many of which 
charge publication fees—that focus on publishing meth-
odologically sound studies regardless of whether they bear 
‘positive’ or ‘negative’ results also helps towards address-
ing these problems. Observational studies are also usually 
much cheaper and easier to plan than RCTs. Researchers do 
need to maintain comprehensive databases from where the 
study populations, including case and controls, are derived. 
Publication bias of observational studies may underlie the 
proposition that the measured effect size is often exagger-
ated. However, a Cochrane review showed that any lack of 
agreement between results of RCTs and observational stud-
ies was not due to different study designs per se, and that 
there were no significant differences in effect size between 
observational studies and RCTs [7].
Conclusions
In conclusion, the current COVID-19 pandemic reminds us 
that RCTs should be conducted with the question of equi-
poise in mind, and that observational studies, when per-
formed and analyzed well, can give valid answers to clinical 
questions in the absence of RCTs. Under the right condi-
tions, observational studies are not much inferior to RCTs.
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